INTRODUCTION {#s1}
============

The incidence of neurodegenerative disease, particularly Parkinson disease (PD) and Alzheimer\'s disease, increased markedly in the last decades \[[@R1], [@R2]\]. Microglia, the major immune cells in the brain, plays a key role in host defence response to injury or infectious agents \[[@R3]\]. Microglia is exquisitely sensitive to brain injury and disease \[[@R4]\]. Overactivation of microglia leads to the production of inflammatory mediators which plays a critical role in the development of neuroinflammation \[[@R5], [@R6]\]. Neuroinflammation has recently been implicated as an important mechanism responsible for the pathological processes of neurodegenerative diseases \[[@R7], [@R8]\]. Therefore, the identification of agents to inhibit neuroinflammation might be an effective approach for the treatment of neurodegenerative diseases.

6-Shogaol, a pungent agent from *Zingiber officinale Roscoe*, has been reported to have anti-tumor and anti-inflammatory effects. 6-Shogaol has been reported to protect against LPS-induced acute lung injury in mice. Also, 6-Shogaol was found to attenuate neuroinflammation and cognitive deficits in animal models of dementia \[[@R9]\]. Furthermore, 6-Shogaol has been reported to inhibit LPS-induced iNOS and COX-2 expression in macrophages \[[@R10]\]. In addition, studies showed that 6-Shogaol could protect against LPS-induced toxicity in murine astrocytes \[[@R11]\]. However, whether 6-Shogaol could inhibit LPS-induced anti-inflammatory response in activated microglial cells remains unclear. In the present study, we evaluated the anti-inflammatory effects of 6-Shogaol in LPS-stimulated BV2 microglia.

RESULTS {#s2}
=======

Effects of 6-Shogaol on cell viability {#s2_1}
--------------------------------------

To test whether 6-Shogaol has cytotoxicity on BV2 microglia, MTT assay were used in this study. The results showed that 6-Shogaol had no cytotoxicity on BV2 microglia at the concentration of 0 to 20 μg/mL (Figure [1](#F1){ref-type="fig"}). Therefore, 6-Shogaol (5, 10, 20 μg/mL) were used in the following experiments.

![Effects of 6-Shogaol on the cell viability of BV2 microglial cells\
Cells were cultured with different concentrations of 6-Shogaol (5, 10, 20 μg/ml) in the absence or presence of 0.5 μg/mL LPS for 24 h. The cell viability was determined by MTT assay. The values presented are the means ± SEM of three independent experiments.](oncotarget-08-42001-g001){#F1}

6-Shogaol inhibited LPS-induced TNF-α, IL-1ß, IL-6, and PGE~2~ production {#s2_2}
-------------------------------------------------------------------------

To investigate the anti-inflammatory effects of 6-Shogaol, the expression of inflammatory mediators were detected in this study by ELISA. As shown in Figure [2](#F2){ref-type="fig"}, LPS dramatically increased the production of TNF-α, IL-1ß, IL-6, and PGE~2~. However, 6-Shogaol concentration dependently down-regulated the production of TNF-α, IL-1ß, IL-6, and PGE~2~ induced by LPS.

![Effects of 6-Shogaol on LPS-induced TNF-α, IL-1ß, IL-6 and PGE~2~ production\
The production of TNF-α, IL-1ß, IL-6 and PGE~2~ were measured by ELISA. The data presented are the means ± SEM of three independent experiments. ^\#^*p* \< 0.05 *vs*. control group; \**p* \< 0.05, \*\**p* \< 0.01 *vs*. LPS group.](oncotarget-08-42001-g002){#F2}

6-Shogaol inhibited LPS-induced NF-κB activation {#s2_3}
------------------------------------------------

NF-κB has been known to be involved in the regulation of inflammatory mediators. To investigate the anti-inflammatory mechanism of 6-Shogaol, LPS-induced NF-κB activation were detected in the present study. The results showed that LPS significantly up-regulated the phosphorylation levels of NF-κB p65 and IκBα. Pretreatment of 6-Shogaol concentration dependently inhibited LPS-induced NF-κB p65 phosphorylation and IκBα phosphorylation and degradation (Figure [3](#F3){ref-type="fig"}).

![Effects of 6-Shogaol on NF-κB expression\
The values presented are the means ± SEM of three independent experiments. ^\#^*p* \< 0.05 *vs*. control group; \**p* \< 0.05, \*\**p* \< 0.01 *vs*. LPS group.](oncotarget-08-42001-g003){#F3}

Effects of 6-Shogaol on PPAR-γ expression {#s2_4}
-----------------------------------------

Previous studies showed that activation PPAR-γ could inhibit LPS-induced NF-κB activation. Thus, we detected whether 6-Shogaol could up-regulated the expression of PPAR-γ. As shown in Figure [4](#F4){ref-type="fig"}, 6-Shogaol increased the expression of PPAR-γ in a concentration dependent manner (Figure [4](#F4){ref-type="fig"}).

![Effects of 6-Shogaol on PPAR-γ expression\
The values presented are the means ± SEM of three independent experiments. ^\#^*p* \< 0.05 *vs*. control group; \**p* \< 0.05, \*\**p* \< 0.01 *vs*. LPS group.](oncotarget-08-42001-g004){#F4}

GW9662 prevented the anti-inflammatory effects of 6-Shogaol {#s2_5}
-----------------------------------------------------------

To further evaluate the anti-inflammatory mechanism of 6-Shogaol, PPAR-γ was blocked by its inhibitor GW9662. As shown in Figure [5](#F5){ref-type="fig"}, our results indicated that the inhibition of 6-Shogaol on TNF-α, IL-1ß, IL-6 and PGE~2~ production were prevented by GW9662. These results suggested that 6-Shogaol exhibited anti-inflammatory effects in BV2 microglia by activating PPAR-γ.

![Effects of PPAR-γ inhibitor GW9662 on the anti-inflammatory effects of 6-Shogaol\
Cells were treated with GW9662 for 12 h. Then, the cells were treated with 6-Shogaol and stimulated by LPS. The productions of inflammatory mediator were detected 24 h after LPS treatment. The values presented are the means ± SEM of three independent experiments. ^\#^*p* \< 0.05 *vs*. control group; \**p* \< 0.05, \*\**p* \< 0.01 *vs*. LPS group.](oncotarget-08-42001-g005){#F5}

DISCUSSION {#s3}
==========

Microglia has been known to play an important role in neurodegenerative diseases \[[@R12]\]. Increasing evidences suggested that controlling the activation of microglia may have protective effects against neurodegenerative diseases \[[@R13]\]. In this study, the results showed that 6-Shogaol inhibited LPS-induced microglia activation by activating PPAR-γ.

Microglia, the prime effector cells in the brain, plays a critical role in immune defense and inflammatory responses \[[@R14]\]. However, overactivation of microglia could lead to the pathological process of neurodegenerative diseases \[[@R15]\]. LPS has the ability to induce microglia activation, which lead to the release of inflammatory mediators \[[@R12], [@R16]\]. These inflammatory mediators, such as TNF-α, IL-1ß, IL-6 and PGE~2~, play an important role in the pathological process of neurodegenerative diseases \[[@R17]\]. In the present study, our results showed that 6-Shogaol significantly inhibited LPS-induced inflammatory mediators production in BV2 microglia. The results indicated that 6-Shogaol exhibited anti-inflammatory effects in BV2 microglia.

It has been reported that NF-κB played a critical role in neuroinflammation \[[@R18]\]. LPS could induce NF-κB activation and inflammatory cytokines release \[[@R19]\]. Inhibition of LPS-induced NF-κB activation could attenuate neuroinflammation \[[@R20]\]. To clarify the anti-inflammatory mechanism of 6-Shogaol, NF-κB activation were measured in this study. We demonstrated that 6-Shogaol significantly inhibited LPS-induced NF-κB activation. PPAR-γ, belongs to a nuclear receptor superfamily, is a ligand-activated transcription factor \[[@R21]\]. Activation of PPAR-γ could regulate metabolism and inflammation \[[@R22]\]. Previous studies PPAR-γ agonists inhibited LPS-induced airway inflammation \[[@R23]\]. Also, PPAR-γ agonists could suppress LPS-induced inflammatory response in RAW264.7 cells \[[@R24]\]. Furthermore, PPAR-γ agonists have been reported to have therapeutic role in diabetes, inflammation, and cancer \[[@R25]\]. In this study, our results showed that 6-Shogaol increased the expression of PPAR-γ. And GW9662, a PPAR-γ inhibitor, could prevent the inhibition of 6-Shogaol on TNF-α, IL-1ß, IL-6 and PGE~2~ production. These results indicated that 6-Shogaol exhibited anti-inflammatory effects in BV2 microglia by activating PPAR-γ.

In conclusion, our results demonstrated that 6-Shogaol suppressed LPS-induced inflammatory mediators production by activating PPAR-γ, which subsequently inhibited LPS-induced NF-κB activation. 6-Shogaol might be an effective agent for the treatment of neurodegenerative diseases.

MATERIALS AND METHODS {#s4}
=====================

Materials {#s4_1}
---------

6-Shogaol (purity \> 98%) was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). LPS (Escherichia coli O55:B5) and MTT were purchased from Sigma (St. Louis, MO, USA). ELISA kits of PGE~2~, TNF-α, IL-6 and IL-1β were purchased from BioLegend (San Diego, CA). PPAR-γ monoclonal antibody was obtained from Santa Cruz Biotechnology (Heidelberg, Germany). NF-κB p65, IκBα, and β-actin monoclonal antibodies were obtained from Cell Signaling Technology Inc (Boston, MA, USA).

Cell culture {#s4_2}
------------

Murine BV2 microglia cells were purchased from China Center for Type Culture Collection (CCTCC, Wuhan, China). The cells were cultured in DMEM with 5% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. The cells were treated with 6-Shogaol 1 h before LPS treatment.

Cell viability {#s4_3}
--------------

For determination of cell viability, MTT assay was applied in this study. BV2 microglia was incubated with 6-Shogaol alone and with LPS for 18 h. Then, the cells were treated with MTT for 4 h and the formazan formed was dissolved with DMSO (150 μl/well). The optical density was determined at 570 nm using a Bio-Rad spectrophotometer.

ELISA assay {#s4_4}
-----------

24 h after LPS treatment, the levels of TNF-α, IL-1β, IL-6, and PGE2 in culture media were tested using commercially available ELISA kits (BioLegend, San Diego, CA). The assay was performed following the instructions provided by the manufacturers.

Western blot analysis {#s4_5}
---------------------

The cells were lysed using RIAP lysis buffer and the concentration was measured by BCA method. Equal amount of protein was resolved using 12% SDS-polyacrylamide gel. The proteins were transferred onto PVDF membranes. The membranes were blocked with 5% skimmed milk and incubated with primary antibodies and HRP-conjugated goat anti-rabbit IgG. The proteins were tested using the chemiluminescence detection system (Amersham, Berkshire, UK). Finally, the bands were analyzed using ImageJ software.

Statistical analysis {#s4_6}
--------------------

Data were presented as means ± SEM. Statistical comparison of the data were analyzed by one-way ANOVA with post-test Neuman-Keuls. A *p value* \< 0.05 was considered as significant.
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